Older Americans Left Out of Costly GLP-1 Craze Expected to Flock to New Program

The U.S. Centers for Medicare & Medicaid Services' 18-month trial program will offer for the first time Novo Nordisk's Wegovy and Eli Lilly's Foundayo and Zepbound as a weight-loss treatment alone.